How Quitting Smoking Can Quickly Lower Risk Of A-Fib
Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.
Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."
"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.
The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.
"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.
The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.
Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:
1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.
2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.
3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.
4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.
5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.
6. Drinking water can help flush nicotine out of your system faster, reducing cravings.
7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.
Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.
Credit: Gilead Sciences
South Africa's National Department of Health has announced that it has received a first consignment of 37,920 doses of the groundbreaking, six-monthly HIV prevention injection, Lenacapavir.
Lenacapavir is the first twice-yearly injectable pre-exposure prophylaxis (PrEP) product that can help tackle the burden of HIV worldwide.
South Africa has the world's largest HIV-positive population of approximately 8 million people, with over 6 million currently on antiretroviral treatment.
“The department will, in the next few weeks, announce the official launch of this game changer where the phased implementation plan will be outlined,” said department spokesperson Foster Mohale, in a statement.
"Lenacapavir is preventive medicine, not a vaccine, considered one of the most exciting HIV prevention advances in years," Mohale said.
The Department noted that the medicine is expected to be sustain nearly half a million people in South Africa over the next two years, the statement said, adding that is will be officially rolled out in May.
Notably, the initial phase will target high-incidence districts and vulnerable groups.
Lenacapavir is a critical tool for reaching the Global AIDS Strategy goal of ending AIDS as a public health threat by 2030.
Lenacapavir injection as an additional PrEP option offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options.
With just two doses per year, lenacapavir is a transformative step forward in protecting people at risk of HIV -- particularly those who face challenges with daily adherence, stigma, or access to health care.
Marketed under the brand name Yeztugo, lenacapavir, developed by global pharma major Gilead Sciences, costs $28,218 per person per year.
However, it is being provided to South Africa through a $29-million USD grant from the Global Fund.
The shot was tested in two major studies involving high-risk groups: one with young women and teenage girls in South Africa and Uganda, and another with gay men and gender-diverse individuals in several countries. In both cases, the results were striking.
The women who received the shot had zero new HIV infections, compared to around 2% in those on daily pills. In the second study, the twice-yearly shot proved just as effective for men and gender non-conforming individuals.
“This really has the possibility of ending HIV transmission,” said Greg Millett of amfAR, The Foundation for AIDS Research.
Yeztugo is administered as two small injections in the abdomen, forming a medication "depot" that slowly releases the drug into the body over six months.
However, people must test negative for HIV before receiving it, as it doesn’t treat existing infections or prevent other sexually transmitted diseases.
Despite its potential, concerns remain over who will actually benefit from lenacapavir.
In the US, only about 400,000 people currently use any form of PrEP — a small fraction of those who could benefit. And structural issues like cuts to public health funding, limited insurance access, and stigma pose significant barriers.
Globally, the challenge is even greater. While Gilead has struck deals with six generic drug makers, including four Indian, to provide low-cost versions of the shot for 120 low-income countries, critics argue that middle-income nations have been left out.
UNAIDS Executive Director Winnie Byanyima noted that at current prices, the shot “will change nothing” for many who need it.
Credit: iStock
Rotavirus has been increasingly detected in wastewater in several California cities, sparking concerns about the risk of the deadly and highly contagious virus in young children.
The virus is highly contagious and known for causing fever, vomiting, and severe watery diarrhea among small children. Older children and adults with weakened immune systems also are vulnerable, according to the US Centers for Disease Control and Prevention (CDC).
As per data from WastewaterSCAN, “high concentrations” of rotavirus have been found in Marin, Redwood City, San Jose, and Santa Cruz, while moderate concentrations have been found in Sacramento, Davis, San Francisco, Sunnyvale, Fremont, Vallejo, and Novato, The Sacramento Bee reported.
"It's extremely contagious," Dr. Monica Gandhi, an infectious disease specialist at UC San Francisco, told SFGATE Thursday, explaining that rotavirus is one of the lesser-known gastrointestinal illnesses.
According to UCSF, approximately 50,000 children in the US are hospitalized with it each year.
Rotaviruses are the most common cause of severe diarrheal disease in infants and young children worldwide.
The virus, a member of the reovirus family, affects the vast majority of children worldwide before the age of 3 years, and in most developing countries before the first birthday.
The virus causing the infection was discovered in 1973, according to the National Institutes of Health. It causes severe diarrhea, often leading to dehydration, which can be severe, requiring hospitalization.
It is transmitted by
WHO-prequalified rotavirus vaccines have been available since 2008, and there are currently four vaccines available. They are all live, oral vaccines.
RotaTeq, Rotavac, and ROTASIIL should be administered in a 3-dose schedule, while a 2-dose schedule should be used for Rotarix. A minimum interval of 4 weeks should be maintained between doses, the WHO said.
In addition, key measures to prevent diarrhea include the following:
Credit: BBC/EPA
Resident doctors in the UK have launched a six-day strike in a dispute with the government over pay.
Tens of thousands of medics have walked out of the National Health Service (NHS) in England on Tuesday, in the 15th strike since March 2023. Their demand: “full pay restoration”.
The six-day walkout comes as the doctors’ group rejected an offer made by the government in March.
According to the British Medical Association (BMA), the government’s proposal failed to reverse years of pay erosion and staffing pressures.
The BMA represents about 55,000 of the resident doctors - formerly known as junior doctors - who make up nearly half of the medical workforce.
The strike is due to run until the morning of April 13, after a 48-hour ultimatum from Prime Minister Keir Starmer passed without agreement.
The BMA argues that doctors are still being paid a fifth less than they were in 2008, once inflation is taken into account. This is despite receiving pay rises worth 33 percent over the past four years.
Dr Jack Fletcher, chair of the BMA's resident doctor committee, told BBC Radio 4's Today program he was "genuinely very sorry" to patients who had care postponed due to the strike, but noted that such delays also occurred "without strike action" because of a lack of specialists and GPs.
"The way out of this is to get around the negotiating table, as we were for eight or so weeks, talk constructively to get a deal, to get us out of this.
Dr Emma Runswick, deputy chair of the BMA Council, told BBC Breakfast they had been close to reaching a deal but "the government decided to move the goalposts quite last minute to reduce the level of investment they were prepared to make".
The strike began at 07:00 BST on Tuesday and promises to cause significant disruption to services.
Dr Melissa Ryan, 45, a pediatric registrar, said she was frustrated that the government was cutting training places and some children were waiting years for assessments, the BBC reported.
The pediatrician who joined dozens of resident doctors in the six-day strike over jobs and pay has said the NHS may "end up without doctors" if the long-running dispute continues.
However, senior medics have being called in to provide cover in emergency settings, still some pre-planned treatments and appointments may get cancelled.
Meanwhile, the NHS has urged patients not to put off seeking help if needed, saying those with emergency and urgent needs should use 999 and 111 as normal, the BBC reported.
While GP services are largely unaffected, the NHS advised patients with prior appointments and treatments scheduled to attend unless told otherwise.
Health Secretary Wes Streeting told BBC Breakfast that 95 percent of appointments were still in place. He also apologized to people affected by cancellations, saying they "deserve better".
He criticized the BMA for not accepting the government’s latest offer and said the government had negotiated with the BMA "in good faith".
According to the British government, the strikes were costing the NHS £50m a day, meaning the health service had lost around £3bn since industrial action started in March 2023. However, a detailed breakdown of costs has not been set out.
Speaking on Times Radio on Tuesday, Streeting said resident doctors had secured the largest pay uplift of any public sector group under the Labour government, but had rejected the offer without putting forward a counter proposal.
© 2024 Bennett, Coleman & Company Limited